Andrew Ambrosy to Aminobutyrates
This is a "connection" page, showing publications Andrew Ambrosy has written about Aminobutyrates.
Connection Strength
2.213
-
Angiotensin receptor-neprilysin inhibitor therapy in heart failure: An end that justifies the means. Am Heart J. 2018 05; 199:176-177.
Score: 0.626
-
Angiotensin-Neprilysin Inhibition in Black Americans: Data From the PIONEER-HF Trial. JACC Heart Fail. 2020 10; 8(10):859-866.
Score: 0.187
-
Angiotensin Receptor-Neprilysin Inhibition Based on History of Heart Failure and Use of Renin-Angiotensin System Antagonists. J Am Coll Cardiol. 2020 09 01; 76(9):1034-1048.
Score: 0.187
-
Improving physical activity and exercise capacity in heart failure. Taking the first step is always the hardest. Eur J Heart Fail. 2020 09; 22(9):1734-1736.
Score: 0.185
-
Sacubitril/Valsartan in Advanced Heart Failure With Reduced Ejection Fraction: Rationale and Design of the LIFE Trial. JACC Heart Fail. 2020 10; 8(10):789-799.
Score: 0.184
-
Initiation of Angiotensin-Neprilysin Inhibition After Acute Decompensated Heart Failure: Secondary Analysis of the Open-label Extension of the PIONEER-HF Trial. JAMA Cardiol. 2020 02 01; 5(2):202-207.
Score: 0.179
-
Should providers prescribe sacubitril/valsartan based on trial eligibility, approval indication, or guideline recommendations? Eur J Heart Fail. 2019 11; 21(11):1398-1401.
Score: 0.173
-
In-hospital initiation of sacubitril/valsartan in acute decompensated heart failure: being in the right place at the right time. Eur J Heart Fail. 2019 08; 21(8):1008-1011.
Score: 0.172
-
Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure. N Engl J Med. 2019 02 07; 380(6):539-548.
Score: 0.165
-
Rationale and design of the comParIson Of sacubitril/valsartaN versus Enalapril on Effect on nt-pRo-bnp in patients stabilized from an acute Heart Failure episode (PIONEER-HF) trial. Am Heart J. 2018 04; 198:145-151.
Score: 0.155